| --- | --- | --- | |-----------------------------|-------|-------| | | | | | | | | | Q1 FY2021 Financial Results | | | | February 4, 2021 | | | Cautionary note regarding forward-looking statements Certain of the statements contained in this presentation are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Words such as "expect," "likely," "outlook," "forecast," "would," "could," "should," "can," "project," " ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM ___________ TO___________ Commission file number 1-16671 AMERISOURCEBERGEN CORPORATION (Exact name of registrant as specified in its charter) Delawa ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED September 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM ___________ TO___________ Commission file number 1-16671 AMERISOURCEBERGEN CORPORATION (Exact name of registrant as specified in its charter) Delaware 23-3079 ...

Financial Data and Key Metrics Changes - Adjusted diluted EPS for Q4 2020 was $1.89, an increase of 17% primarily due to higher operating income [30] - Consolidated revenue reached $49.2 billion, up 8%, driven by growth in both Pharmaceutical Distribution Services and Global Commercialization Services [30] - Consolidated operating income increased to $530 million, up 16% from the previous year [31] - Full year consolidated revenue was $189.9 billion, up 6%, with operating income growing 7% to $2.2 billion [37] Business Line Data and Key Metrics Changes - Pharmaceutical Distribution Services segment revenue was $47 billion, up 8%, benefiting from strong specialty product sales [33] - Operating income for the Pharmaceutical Distribution segment increased about 15% to $426 million [34] - The Other segment, including Global Commercialization Services and Animal Health, reported total revenue of $2 billion, up 11%, with MWI's revenue growing 8% [35] Market Data and Key Metrics Changes - The company noted strong utilization trends for biosimilars, which are expected to be a long-term growth driver [18] - The adjusted effective tax rate for fiscal 2020 was 20.8%, consistent with the previous year [39] Company Strategy and Development Direction - The company aims to leverage its strengths in specialty distribution and enhance customer-centric services [26] - Focus on maintaining a balanced approach to capital deployment, prioritizing internal investments and strategic M&A opportunities [70] - The company is committed to supporting its customers through innovative solutions and enhancing operational efficiency [21][26] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's resilience and ability to navigate challenges posed by the COVID-19 pandemic [28] - The company anticipates mid-single-digit revenue and operating income growth for fiscal 2021, reflecting strong underlying business performance [42][43] - Management highlighted the importance of biosimilars and the company's role in improving patient access to medications [58] Other Important Information - The company recorded a GAAP pretax charge of $6.6 billion related to opioid lawsuits, which is excluded from adjusted non-GAAP results [36] - The company has committed to reducing greenhouse gas emissions by more than 5% over the past year [24] Q&A Session Summary Question: Guidance on pharmaceutical segment growth - Management indicated that mid-single-digit EBIT growth reflects strong growth across multiple businesses, with a tailwind from the exit of PharMEDium [54][55] Question: Impact of Strategic National Stockpile initiative on guidance - Management confirmed that the contract is included in the numbers but did not provide specific guidance related to it [60][62] Question: Margin opportunities with biosimilars - Management noted that biosimilars present higher margin opportunities compared to traditional branded drugs, contributing positively to operating margins [63][65] Question: Capital expenditures and deployment strategy - Management expects capital expenditures to increase to about $400 million, focusing on supporting growth and enhancing efficiency [69][70] Question: Opioid litigation and capital deployment - Management emphasized that capital deployment priorities remain unchanged despite the potential settlement, focusing on internal investments and shareholder returns [75]

| --- | --- | |-------|-------| | | | | | | Cautionary Note Regarding Forward-Looking Statements 2 Certain of the statements contained in this presentation are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Words such as "expect," "likely," "outlook," "forecast," "would," "could," "should," "can," "project," "intend," "plan," "continue," "sustain," "synergy," "on track," "believe," "seek," "estimate," "anti ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM ___________ TO___________ Commission file number 1-16671 AMERISOURCEBERGEN CORPORATION (Exact name of registrant as specified in its charter) | --- | -- ...

AmerisourceBergen Corporation (ABC) Q3 2020 Earnings Conference Call August 5, 2020 8:30 AM ET Company Participants Bennett Murphy - Head of Investor Relations Steve Collis - Chairman, President & Chief Executive Officer Jim Cleary - Executive Vice President & Chief Financial Officer Conference Call Participants Steven Valiquette - Barclays Eric Coldwell - Baird Lisa Gill - JPMorgan George Hill - Deutsche Bank Charles Rhyee - Cowen Ricky Goldwasser - Morgan Stanley Eric Percher - Nephron Research Elizabeth ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | --- | |---------------------------|------------------------------------------------------------------|----------------------------------------------| | FOR THE TRANSITI ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM ___________ TO___________ Commission file number 1-16671 AMERISOURCEBERGEN CORPORATION (Exact name of registrant as specified in its charter) Delawa ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED September 30, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | --- | |---------------------------|--------------------------------------------------------------------------------------|------------------------------------------------| | | ...